Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

“As time goes on, they’re more willing to share their story because they get so many compliments,” she said. “The person who is next to them says, ‘Tell me your secret,’ and they may whisper my name ...

Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...